• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2019.14097

Рaraneoplastic thrombophilias. From Trousseau to present days

[Lecture. Clinical decisions support]
Leonid Dvoretsky;

Venous thrombosis of various localization in patients with malignant tumors described for the first time by A. Trousseau, is an important problem of clinical medicine (paraneoplastic thrombophilia). In some cases, venous thrombosis can be the first manifestation of a malignant tumor. Data on the epidemiology, developmental mechanisms, clinical and prognostic significance of venous thrombosis in patients with malignant tumors are given. The need for a thorough study of patients with the presence of idiopathic venous thrombosis in order to identify the tumor process is emphasized.

Download

References:
1. Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale d’Hotel-Dieu de Paris. Paris: JB Balliere et Fils. 1865;3:654-812.
2. Arnautov G. D. Meditsinskaya terminologiya na pyati yazykakh. Meditsina i fizkul’tura. Sofiya, 1966. (In Russ).
3. Chaturvedi S., Sidana S., Elson R., Khorana A. A., McCrae K. R. Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoSOne. 2014;9:e94048. https://doi.org/10.1371/journal.pone.0094048
4. Dammacco F., Vacca A., Procaccio P., Ria R., Marech I., Racanelli V. Cancer-related coagulopathy (Trousseaus syndrome): review of the literature and experience of a single center of internal medicine. Clin. Exp. Med. 2013;13:85- 97. https://doi.org/10.1007/s10238-013-0230-0
5. James T., Matheson N. Thrombophlebitis in cancer. Practitioner. 1935;34:683-684.
6. Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am. J. Cancer. 1938;34:566585.
7. Ackerman R., Estes J. Prognosis in idiopathic thrombophlebitis. Ann. Intern. Med. 1951;34:902-910. https://doi.org/10.7326/0003-4819-34-4-902
8. Thompson C., Rodgers R. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am. J. Med. Sci. 1952;223:469.
9. Gore J., Appelbaum J., Green H., Dexter L., Dalen J. Occult Cancer in Patients with Acute Pulmonary Embolism. Ann. Intern. Med. 1982;96(5):556-560. https://doi.org/10.7326/0003-4819-96-5-556
10. Rickles F., Levine M. N. Epidemiology of Thrombosis in Cancer. Аcta Haematol. 2001;106:6-12. https://doi.org/10.1159/000046583
11. Мonreal M., Fernandez-Llamazares J., Perandreu J., Urrutia A.,Sahuquillo J. C., Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb. Haemost. 1997;78:1316-1318.
12. Geerts W., Bergqvist D., Pineo G., Heit J., Samama C. [et al.]. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:381S–453S. https://doi.org/10.1378/chest.08-0656
13. Sørensen H., Mellemkjaer L., Olsen J., Baron J. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 2000;343:18461850. https://doi.org/10.1056/NEJM200012213432504
14. Kolomansky A., Hoffman R., Sarig G., Brenner B., Haim N. Prospective evaluation of patients hospitalized with venous thromboembolism: comparison between cancer and non-cancer patients. Isr. Med. Assoc. J. 2006;8(12):848- 852.
15. Khorana A. A. Malignancy, thrombosis and Trousseau: the case for an eponym. J. Thromb. Haemost. 2003;1: 2463- 2465.
16. Vorobev A. V., Makatsariya A. D., Brenner B. Trousseau’s syndrome: a forgotten past or a current present? Akusherstvo i ginekologiya. – Obstetrics and Gynecology. 2018;2:27-34. (In Russ.). https://doi.org/10.18565
17. Ikushima S., Ono R., Fukuda K., Sakayori M., Awano N., Kondo K. Trousseau’s syndrome: cancer-associated thrombosis. Japanese Journal of Clinical Oncology. 2016;46(3):204-208. https://doi.org/10.1093/jjco/hyv165
18. Sack G., Levin J., Bell W. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56(1):1-37.
19. Davila M., Robles-Carrillo L., Unruh D., Huo Q., Gardiner C. [et al.]. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation? Thromb. Haemost. 2014;12:186-196. https://doi.org/10.1111/jth.12475
20. Kocatiirk B., Versteeg H. Tissue factor isoformsin cancer and coagulation: may the best isoformwin. Thromb. Res. 2012;129:69-75. https://doi.org/10.1016/S0049-3848(12)70020-8
21. Toth B., Liebhardt S., Steinig K., Ditsch N., Rank A. [et al.]. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thrombosis and Haemostasis. 2008;100(4):663-669. https://doi.org/10.1160/TH07-10-0602
22. Hron G., Kollars M., Weber H., Sagaster V., Quehenberger P. [et al.]. Tissue factor positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thrombosis and Haemostasis. 2007;97(1):119-123.
23. Kim H., Song K., Park Y., Kang Y., Lee Y. [et al.]. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. European Journal of Cancer. 2003;39(2):184-191.
24. Geddings J., Mackman N. Tumor-derived tissuefactor- positive microparticles and venous thrombosisincancer patients. Blood. 2013;122:1873-1880. https://doi.org/10.1182/blood-2013-04-460139
25. Jozwik М., Szajda S., Skrzydlewski Z., Jozwik M., Sulkowski S. The activity of cancer procoagulant in cases of uterine leiomyomas. European Journal of Gynaecological Oncology. 2005;26(4):407-410.
26. Kazmierczak М., Lewandowski К., Wojtukiewicz M., Turowiecka Z., Kołacz E. [et al.]. Cancer procoagulant in patients with adenocarcinomas. Blood Coagulation and Fibrinolysis. 2005;6(8):543-547. https://doi.org/1097/01.mbc.0000188413.32859.b2
27. Bick R. Cancer-associated thrombosis. N. Engl. J. Med. 2003;349:109-111. https://doi.org/10.1056/NEJMp030086
28. Jovin T., Boosupalli V., Zivkovic S., Wechsler L., Gebel J. High titers of CA125 may be associated with recurrent ischemic strokes in patients with cancer. Neurology. 2005;64:1944-1945. https://doi.org/10.1212/01.WNL.0000163850.07976.63
29. Claussen C., Rausch A. V., Spath B. Clinical significance of hemostatic activation markers in women with suspected ovarian cancer. Oncol. Res. Treat. 2014;37:669.
30. Lo L., Valentine H., Harrison J., Hayes S., Welch I. [et al.]. Tissue factor expression in the metaplasia-adenoma-carcinomasequence of gastric cancer in a European population. Br. I Cancer. 2012;107:1125-1130. https://doi.org/10.1038/bjc.2012.363
31. Demers M., Wagner D. D. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin. Thromb. Hemost. 2014;40:277-283. https://doi.org/10.1055/s-0034-1370765
32. Thaler I., Ay C., Mackman N., Metz-Schimmerl S., Stift J. [et al.]. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur. J. Clin. Invest. 2013;43:277-285. https://doi.org/10.1111/eci.12042
33. Kemik О., Sumer А., Kemik A., Hasirci I., Purisa S. [et al.]. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World Journal of Surgical Oncology. 2010;8:85. https://doi.org/10.1186/1477-7819-8-85
34. Demers M., Krause D., Schatzberg D., Martinod K., Voorhees J. [et al.]. Cancers predispose neutrophils to release extracellular dna traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 2012;109:13076- 13081. https://doi.org/10.1073/pnas.1200419109
35. Baluka D., Urbanek T., Lekstan A., Swietochowska E., Wiaderkiewicz [et al.]. The role of the tissue plasminogen activator as a prognostic and differentiation factor in patients with pancreatic cancer and chronic pancreatitis. Journal of Physiology and Pharmacology. 2016;67(1); 93-101.
36. Przhedetsky Yu. V., Frantsiyants E. M., Komarova E. F., Pozdnyakova V. V., Sharay E. A. Plasminogen activator inhibitor PAI-1 in tumor and perifocal tissues of basal cell carcinoma of the skin. Mezhdunarodnyy zhurnal eksperimental’nogo obrazovaniya. – International Journal of Experimental Education. 2015;5:140. (In Russ.).
37. Kwaan H., Keer H. Fibrinolysis and cancer. Semin. Thromb. Haemost. 1990;16:230-235. https://doi.org/10.1055/s-2007-1002674
38. Buller H., ten Cate J. Primary venous thromboembolism and cancer screening. N. Engl. J. Med. 1998;338:1221- 1222. https://doi.org/10.1056/NEJM199804233381709
39. Prandoni P., Piccioli A. Thrombosis as a harbinger of cancer. Curr. Opin. Hematol. 2006;13:362-365. https://doi.org/10.1097/01.moh.0000239709.47921.04
40. Piccioli A., Lensing A., Prins M., Falanga A., Scannapieco G [et al.]. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J. Thromb. Haemost. 2004;2: 884-889.https://doi.org/10.1111/j.1538-7836.2004.00720.x
41. Di Nisio M., Otten H., Piccioli A., Lensing A., Prandoni P. [et al.]. Decision analysis for cancer screening in idiopathic venous thromboembolism. J. Thromb. Haemost. 2005;3:2391-2396. https://doi.org/10.1111/j.1538-7836.2005.01606.x
42. Matzdorff A., Riess H., Bergmann F., Bisping G., Koschmieder S. [et al.]. Cancer Screening in Patients with Idiopathic Venous Thromboembolism – a Position Paper of the German Society of Hematology and Oncology Working Group on Hemostasis. Oncol. Res. Treat. 2015;38:454-458. https://doi.org/10.1159/000437451
43. Robertson L., Yeoh S., Stansby G., Agarwal R. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database Syst Rev. 2017;23(8):CD010837. https://doi.org/10.1002/14651858.CD010837.pub3
44. van Es N., Le Gal G., Otten H. Hans-Martin, Hans-Martin Robin Ph., Piccioli A. [et al.]. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis of Individual Patient Data. Ann. Intern. Med. 2017;167(6):410-417. https://doi.org/10.7326/M17-0868
45. Prandoni P., Lensing A., Piccioli A., Bernardi E., Simioni P. [et al.]. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484. https://doi.org/10.1182/blood-2002-01-0108
46. Douketis J., Crowther M., Foster G., Ginsberg J. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am. J. Med. 2001;110:515.
47. Lyman G., Khorana A., Kuderer N., Lee A., Arcelus J. [et al.]. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 2013;31:2189-2204. https://doi.org/10.1200/JCO.2013.49.1118
48. Kakkar A., Levine M., Pinedo H., Wolff R., Wong J. Venous thrombosis in cancer patients: insights from the frontline survey. Oncologist. 2003;8:381-388.
49. Cohen A., Davidson B., Gallus A., Lassen M., Prins M. [et al.]. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325- 329. https://doi.org/10.1136/bmj.38733.466748.7C
50. Leizorovicz A., Cohen A., Turpie A., Olsson C., Vaitkus P., Goldhaber S. on behalf of the prevent Medical Thromboprophylaxis Study Group. Randomized, placebocontrolled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-879. https://doi.org/10.1161/01.CIR.0000138928.83266.24
51. Akl E., Vasireddi S., Gunukula S., Barba M., Sperati F. [et al.]. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst. Rev. 2011;6:CD006649. https://doi.org/10.1002/14651858.CD006649.pub3
52. Streiff M., Bockenstedt P. L., Cataland S. R., Chesney C., Eby C. [et al.]. Venous thromboembolic disease. J. Natl. Compr. Canc. Netw. 2013;11:1402-1429.
53. Schulman S., Kearon C., Kakkar A., Mismetti P., Schellong S. [et al.]. On behalf of the re -cover study group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009;361:2342- 2352. https://doi.org/10.1056/NEJMoa0906598
54. Bauersachs R., Berkowitz S., Brenner B., Buller H., Decousus H. [et al.]. On behalf of the Einstein investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 2010;363:2499-2510. https://doi.org/10.1056/NEJMoa1007903

Keywords: venous thrombosis, venous thromboembolism, malignant tumors, paraneoplastic thrombophilia